unlike some i've never said that P2O's first sale won't
unlike some i've never said that P2O's first sale won't matter .. it will
but i'm actually able to think across a few levels .. which is why imo this next
PR out of RH is his most important to date as CEO ..
in addition to P2O's first sale .. i'm looking for ancillary material events filed
including RH's seating of an independent BoD and P2O holding their first
AGM since Dec 2013
i find it rather revealing that the same multi/s who whined 24/7/365 for years
about all those (alleged) sells are now extolling ask hits ..
i found it amusing back in 2011/2012 .. that the PRO side of the originals
resented documentation of PTOI tapes of trades (glikbarg trust anyone)
and the CON side ignored them .. now the CON side resents them and
is reduced to that old chestnut of *turning* re: divert and deflect that they
are the result of an agreement with the company from 2010 .. seriously
deflate that idea .. zero PTOI shares let alone money has come my way from
anyone .. and one of the reasons i so look forward to P2O's first sale is the
ability to have interchangeables (and non) exposed via discovery .. but crews
and trolls are just the tip of the iceberg .. this isn't their money funding those
efforts
who sent the story to the author of the first hit piece? .. for its *timing* in July 2010
(with CSTI sent over to aid and abet NN)?
why did the dolts *hide* the letter from 9.2010 until almost one year later (8.2011)
the whole pattern played out by NON RETAIL is so obvious with hind sight
one has to ask how could the SEC miss it .. for so many years allowing
*imo* BILLIONS to go to a very select group who controlled so many OTC outcomes
no one spends time on any SMB without there being a financial interest
no one
4kids
1
Plastic2Oil, Inc. (PTOI) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...
Continue Reading
Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...
Continue Reading
A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...
Continue Reading
Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...
Continue Reading
Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...
Continue Reading
A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...
Continue Reading
Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...
Continue Reading
By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...
Continue Reading
Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...
Continue Reading
August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...
Continue Reading